WALTHAM, Mass., Jan. 12, 2016 /PRNewswire/ -- Respiratory Motion, Inc. today announced that veteran corporate executive Diana Gelston joins the company as chief commercial officer. She brings over two decades of experience and leadership in healthcare technology organizations, overseeing sales, marketing, strategy and transformation.
Gelston was most recently the corporate vice president and market leader of Business Transformation for Philips Health Systems, North America, overseeing efforts to streamline the company's commercial operations.
Previously, as a vice president of sales for Philips, she built a $400 million corporate alliance start-up to solve economic challenges within strategic accounts.
From her work at Philips and Hewlett-Packard, Gelston has a wealth of experience in developing and deploying successful distribution channels for healthcare devices, informatics and business consulting practices to drive growth in new and existing markets.
"The ExSpiron™ Respiratory Volume Monitoring (RVM) technology is unique in the market," she said. "A compelling reason for joining Respiratory Motion is the transformative effect of its technology on patient safety in patients who are at risk for respiratory compromise."
Gelston joins Respiratory Motion at a time when a growing number of health care systems are searching for improved respiratory monitoring technology to replace unreliable systems.
"The sales channel development and leadership that Diana brings to Respiratory Motion will be invaluable as we continue to expand globally," said Dr. Jenny E. Freeman, president and CEO of Respiratory Motion, which manufactures The ExSpiron monitor, the only available non-invasive, continuous minute ventilation monitor that provides data previously available only for intubated patients.
In the hospital, changes in breathing status often precede deterioration towards respiratory depression and cardiac arrest. Each year, cardiopulmonary arrests may reach 160,000 cases and lead to thousands of deaths. Commonly, cardiopulmonary arrests are preceded by respiratory events.
The U.S. Department of Health & Human Services' Agency for Healthcare Research and Quality finds the annual costs of respiratory insufficiency, arrest and failure was $7.8 billion in 2007, making respiratory issues one of the fastest drivers of hospital inpatient cost increases in the United States.
Minute ventilation is used to monitor the amount of air actually breathed by a patient. In 2012, Respiratory Motion won U.S. Food and Drug Administration clearance for its revolutionary ExSpiron monitoring system, the first technology to provide continuous, non-invasive respiratory volumes in spontaneously breathing patients.
About Respiratory Motion, Inc.
Respiratory Motion, Inc. is a medical device company based in Waltham, Mass., that develops innovative technology to monitor respiration and help clinicians and hospitals improve patient safety and outcomes. The company's monitoring systems can identify patients who are at risk for potentially life-threatening respiratory depression. This allows physicians to prevent the dangerous condition before it harms a patient. To learn more, visit www.respiratorymotion.com.
SOURCE Respiratory Motion, Inc.